In melanomas and gliomas, enhanced SPARC expression associates with a highly aggressive tumor phenotype, whereas in pancreatic adenocarcinoma, acute myeloid leukemia, and ovarian and colorectal carcinomas, SPARC behaves as a tumor suppressive molecule [174,175,176,177]. This evidence concerns the gene SPARC and pancreatic adenocarcinoma.